Dimericon Therapeutics
PrivateLast Round
Seed
May 1, 2023
Total Funding Raised
$14M
Company Overview
Dimericon Therapeutics is a biotechnology company that develops precision oncology therapeutics targeting intracellular protein-protein interactions using crosslinked helix dimer modalities.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dimericon Therapeutics Comparables
Compare Dimericon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| A-Alpha Bio | 79% | |
| SPIMA Therapeutics | 75% | |
| PRISM BioLab Co., Ltd. | 73% |
Dimericon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 1, 2023 |
Dimericon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Seed |
| AbbVie Ventures | Seed |
| CARMA FUND | Seed |
| High-Tech Gründerfonds | Seed |
| Blood Cancer United | Seed |
Dimericon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Dimericon Therapeutics's valuation, stock price, and market status.
Is Dimericon Therapeutics a public or private company?
Dimericon Therapeutics is a private company.
What is the current stock price of Dimericon Therapeutics?
Dimericon Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Dimericon Therapeutics worth (valuation)?
Valuation information for Dimericon Therapeutics is not publicly available.
Can I buy Dimericon Therapeutics stock?
Dimericon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Dimericon Therapeutics's last funding round?
Dimericon Therapeutics's most recent funding round was Seed on May 1, 2023.
Who are the main investors in Dimericon Therapeutics?
Key investors in Dimericon Therapeutics include BioMedPartners, AbbVie Ventures.
Will Dimericon Therapeutics IPO soon?
No public IPO plans have been announced for Dimericon Therapeutics.
How can I track Dimericon Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Dimericon Therapeutics's secondary market activity and sign up for updates.